PRESS RELEASE published on 02/06/2024 at 15:02, 7 months 13 days ago Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research has reiterated its BUY rating and CAD 3.80 price target for Sernova Corp (ISIN: CA81732W1041) based on the company's financial statement release and business update for FY 22/23. Sernova's achievements in diabetes treatment and potential partnering deal are anticipated to drive stock performance First Berlin Equity Research Sernova Corp FY 22/23 Diabetes Treatment Partnering Deal
PRESS RELEASE published on 10/19/2023 at 15:57, 11 months ago Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): BUY
PRESS RELEASE published on 09/14/2023 at 22:06, 1 year ago Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
PRESS RELEASE published on 09/13/2023 at 13:01, 1 year ago Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
PRESS RELEASE published on 05/03/2023 at 13:01, 1 year 4 months ago Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
PRESS RELEASE published on 04/10/2023 at 13:05, 1 year 5 months ago Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
PRESS RELEASE published on 03/22/2023 at 12:04, 1 year 5 months ago Sernova: Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions
PRESS RELEASE published on 03/14/2023 at 12:05, 1 year 6 months ago Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
PRESS RELEASE published on 03/08/2023 at 13:05, 1 year 6 months ago Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
PRESS RELEASE published on 03/02/2023 at 13:05, 1 year 6 months ago Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
Published on 09/19/2024 at 17:30, 1 hour 4 minutes ago Airborne Geophysical Survey Completed at Pine Channel Gold Project, Saskatchewan
Published on 09/19/2024 at 17:00, 1 hour 34 minutes ago Cypress Creek Consulting Advises Charter Communications on Inaugural Securitization Financing Facility
Published on 09/19/2024 at 15:45, 2 hours 49 minutes ago eLearners Make eLearning a Daily or Weekly Habit, Voices' eLearning Report Finds
Published on 09/19/2024 at 15:20, 3 hours 14 minutes ago Taurus secures "Best Digital Assets Solution" at 2024 Global BankTech Awards
Published on 09/19/2024 at 15:01, 3 hours 33 minutes ago ful. CashPay: Revolutionizing Healthcare Access for Employers With Uninsured Team Members
Published on 09/19/2024 at 17:52, 41 minutes ago PILOT 28 : FIGEAC AÉRO remporte 3 nouveaux contrats sur l'A320 pour 65 millions d'euros
Published on 09/19/2024 at 17:52, 41 minutes ago PILOT 28: FIGEAC AÉRO secures 3 new wins on the A320 airframe for 65 million euros
Published on 09/19/2024 at 17:52, 42 minutes ago EQS-Adhoc: SMT Scharf AG: New CEO joins the Managing Board
Published on 09/19/2024 at 17:45, 49 minutes ago AFG Holding SA acquiert une participation majoritaire dans le groupe allemand Access Holding et prend ainsi le contrôle de
Published on 09/19/2024 at 17:45, 49 minutes ago Gimv draagt helft van participatie in Infravest over aan WorxInvest (communicatie in toepassing van artikel 7:97 WVV)
Published on 09/19/2024 at 17:45, 49 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)
Published on 09/19/2024 at 17:45, 49 minutes ago Gimv sells half of participation in Infravest to WorxInvest (communication pursuant to article 7:97 BCAC)